ALNY - Alnylam launches mid-stage zilebesiran study in hypertension

Alnylam Pharmaceuticals (ALNY) has initiated Phase 2 KARDIA-1 study evaluating the efficacy and safety of zilebesiran for the treatment of hypertension.Zilebesiran will be evaluated as monotherapy across different doses administered quarterly and biannually. The primary endpoint is the change from baseline in systolic blood pressure after three months of treatment.Additional endpoints will include change from baseline in blood pressure at six months, time-averaged reduction of blood pressure as a measure of tonic control, and safety.The Company will host an “RNAi Roundtable” webinar today at 10:00 a.m. ET to discuss the zilebesiran program.

For further details see:

Alnylam launches mid-stage zilebesiran study in hypertension